DK1625154T3 - Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme - Google Patents

Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme

Info

Publication number
DK1625154T3
DK1625154T3 DK04731118.8T DK04731118T DK1625154T3 DK 1625154 T3 DK1625154 T3 DK 1625154T3 DK 04731118 T DK04731118 T DK 04731118T DK 1625154 T3 DK1625154 T3 DK 1625154T3
Authority
DK
Denmark
Prior art keywords
hepatitis
binding pocket
polymerase inhibitor
ns5b polymerase
inhibitor binding
Prior art date
Application number
DK04731118.8T
Other languages
English (en)
Inventor
Rene Coulombe
Pierre Louis Beaulieu
Eric Jolicoeur
George Kukolj
Steven Laplante
Marc-Andre Poupart
Original Assignee
Boehringer Ingelheim Int
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Boehringer Ingelheim Int filed Critical Boehringer Ingelheim Int
Application granted granted Critical
Publication of DK1625154T3 publication Critical patent/DK1625154T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • C07K14/08—RNA viruses
    • C07K14/18—Togaviridae; Flaviviridae
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/005—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from viruses
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/16—Drugs for disorders of the alimentary tract or the digestive system for liver or gallbladder disorders, e.g. hepatoprotective agents, cholagogues, litholytics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/12—Antivirals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/10—Transferases (2.)
    • C12N9/12—Transferases (2.) transferring phosphorus containing groups, e.g. kinases (2.7)
    • C12N9/1241—Nucleotidyltransferases (2.7.7)
    • C12N9/127—RNA-directed RNA polymerase (2.7.7.48), i.e. RNA replicase
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2299/00—Coordinates from 3D structures of peptides, e.g. proteins or enzymes
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2770/00—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA ssRNA viruses positive-sense
    • C12N2770/00011—Details
    • C12N2770/24011—Flaviviridae
    • C12N2770/24211—Hepacivirus, e.g. hepatitis C virus, hepatitis G virus
    • C12N2770/24222—New viral proteins or individual genes, new structural or functional aspects of known viral proteins or genes

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Genetics & Genomics (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Zoology (AREA)
  • Virology (AREA)
  • Wood Science & Technology (AREA)
  • Biochemistry (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Microbiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Communicable Diseases (AREA)
  • Oncology (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Peptides Or Proteins (AREA)
  • Enzymes And Modification Thereof (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Investigating Or Analysing Biological Materials (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
DK04731118.8T 2003-05-09 2004-05-05 Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme DK1625154T3 (da)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US46960403P 2003-05-09 2003-05-09
PCT/CA2004/000676 WO2004099241A1 (en) 2003-05-09 2004-05-05 Hepatitis c virus ns5b polymerase inhibitor binding pocket

Publications (1)

Publication Number Publication Date
DK1625154T3 true DK1625154T3 (da) 2014-02-24

Family

ID=33435247

Family Applications (1)

Application Number Title Priority Date Filing Date
DK04731118.8T DK1625154T3 (da) 2003-05-09 2004-05-05 Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme

Country Status (12)

Country Link
US (1) US7386398B2 (da)
EP (1) EP1625154B1 (da)
JP (1) JP4584909B2 (da)
KR (1) KR101164070B1 (da)
CN (1) CN100457776C (da)
AU (1) AU2004235848B2 (da)
CA (1) CA2522574C (da)
DK (1) DK1625154T3 (da)
ES (1) ES2456702T3 (da)
IL (1) IL171800A (da)
MX (1) MXPA05012101A (da)
WO (1) WO2004099241A1 (da)

Families Citing this family (44)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW200517381A (en) 2003-08-01 2005-06-01 Genelabs Tech Inc Bicyclic heteroaryl derivatives
US7153848B2 (en) 2004-08-09 2006-12-26 Bristol-Myers Squibb Company Inhibitors of HCV replication
US7816348B2 (en) 2006-02-03 2010-10-19 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
US8512352B2 (en) * 2007-04-17 2013-08-20 Lazarus Effect, Inc. Complex wire formed devices
CA2693495A1 (en) * 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009018657A1 (en) 2007-08-03 2009-02-12 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
WO2009033183A2 (en) * 2007-09-08 2009-03-12 University Of Florida Research Foundation Compounds and methods for treatment of hcv and conditions associated with cd81 binding
BRPI0703586B1 (pt) * 2007-10-19 2018-02-06 Braskem S.A Catalisador metaloceno suportado, e, copolímeros de etileno com alfa-olefinas de alto e ultra alto peso molecular
WO2009076747A1 (en) 2007-12-19 2009-06-25 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors
NZ593808A (en) * 2008-12-03 2014-04-30 Presidio Pharmaceuticals Inc Inhibitors of hcv ns5a
WO2010081149A1 (en) * 2009-01-12 2010-07-15 Glaxosmithkline Llc Anti-viral compounds, compositions, and methods of use
WO2010096777A1 (en) * 2009-02-23 2010-08-26 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
JP2012532102A (ja) * 2009-06-30 2012-12-13 シガ・テクノロジーズ・インコーポレーテッド デングウイルス感染の治療法および予防法
US8993604B2 (en) 2009-06-30 2015-03-31 Siga Technologies, Inc. Treatment and prevention of dengue virus infections
US20110053892A1 (en) * 2009-08-31 2011-03-03 Martin Leivers Imidazo[4,5-d]Pyridazine Compounds For Treating Viral Infections
US20110065782A1 (en) * 2009-09-15 2011-03-17 Malliavin Therese Methods of identifying compounds that inhibit the activation of a biomolecule and methods of treatment using the compounds
TW201138786A (en) * 2010-02-19 2011-11-16 Glaxo Group Ltd Therapeutic compounds
WO2011150243A1 (en) * 2010-05-28 2011-12-01 Presidio Pharmaceuticals, Inc. Inhibitors of hcv ns5a
WO2012040389A2 (en) 2010-09-22 2012-03-29 Presidio Pharmaceuticals, Inc. Substituted bicyclic hcv inhibitors
WO2012050918A2 (en) 2010-09-29 2012-04-19 Presidio Pharmaceutical, Inc. Tricyclic fused ring inhibitors of hepatitis c
NZ609564A (en) 2010-10-26 2015-06-26 Presidio Pharmaceuticals Inc Inhibitors of hepatitis c virus
EP2635675B1 (en) * 2010-11-02 2016-01-06 Probiodrug AG Crystal structure of isoglutaminyl cyclase
CA2817840A1 (en) 2010-11-17 2012-05-24 Gilead Sciences, Inc. Antiviral compounds
WO2012083059A1 (en) * 2010-12-15 2012-06-21 Abbott Laboratories Anti-viral compounds
AU2012295290B2 (en) 2011-08-12 2017-06-15 Sanford-Burnham Medical Research Institute Quinazolinone analogs and use of quinazolinone analogs for treating or preventing certain viral infections
PT2907816T (pt) 2011-11-16 2018-10-18 Gilead Pharmasset Llc Imidazolilimidazóis condensados como compostos antivirais
SI2794628T1 (sl) 2011-12-20 2017-07-31 Riboscience Llc 4'-azido-3'-fluoro substituirani nukleozidni derivati kot inhibitorji podvojevanja RNA HCV
CA2863282A1 (en) * 2012-01-13 2013-07-18 Gilead Pharmasset Llc Crystal structure of hcv polymerase complexes and methods of use
US20130309196A1 (en) 2012-05-16 2013-11-21 Gilead Sciences, Inc. Antiviral compounds
US10034893B2 (en) * 2013-02-01 2018-07-31 Enanta Pharmaceuticals, Inc. 5, 6-D2 uridine nucleoside/tide derivatives
US9167288B2 (en) 2013-03-15 2015-10-20 Universal Electronics Inc. System and method for optimizing memory usage in a universal controlling device
KR102241198B1 (ko) 2013-05-16 2021-04-15 리보사이언스 엘엘씨 4'-플루오로-2'-메틸 치환된 뉴클레오시드 유도체
MX2015015781A (es) 2013-05-16 2016-06-02 Riboscience Llc Derivados de nucleósido 4'-azido, 3'-deoxi-3'-fluoro sustituido.
US20180200280A1 (en) 2013-05-16 2018-07-19 Riboscience Llc 4'-Fluoro-2'-Methyl Substituted Nucleoside Derivatives as Inhibitors of HCV RNA Replication
SG11201601274QA (en) * 2013-08-26 2016-03-30 Enanta Pharm Inc Cyclosporin analogues for preventing or treating hepatitis c
AU2014311827B2 (en) 2013-08-27 2017-09-14 Gilead Sciences, Inc. Combination formulation of two antiviral compounds
TWI721947B (zh) 2014-06-11 2021-03-21 美商基利法瑪席特有限責任公司 抗病毒化合物的固態形式
WO2016033164A1 (en) 2014-08-26 2016-03-03 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
US9669095B2 (en) 2014-11-03 2017-06-06 Enanta Pharmaceuticals, Inc. Cyclosporin analogues for preventing or treating hepatitis C infection
WO2016073756A1 (en) 2014-11-06 2016-05-12 Enanta Pharmaceuticals, Inc. Deuterated nucleoside/tide derivatives
US9732110B2 (en) 2014-12-05 2017-08-15 Enanta Pharmaceuticals, Inc. Nucleoside and nucleotide derivatives
CN104530189B (zh) * 2014-12-16 2017-11-14 郑州大学第一附属医院 丙型肝炎病毒ns5b rna聚合酶抑制多肽序列及其用途
AU2018335411B2 (en) 2017-09-21 2024-06-27 Riboscience Llc 4'-fluoro-2'-methyl substituted nucleoside derivatives as inhibitors of HCV RNA replication
WO2023172635A1 (en) * 2022-03-08 2023-09-14 Emory University Predictive model for variants associated with drug resistance and theranostic applications thereof

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5528559A (en) * 1995-06-23 1996-06-18 Motorola, Inc. Multiple display timepiece
WO1999057253A2 (en) * 1998-05-04 1999-11-11 Vertex Pharmaceuticals Incorporated Crystallizable jnk complexes
US6434489B1 (en) * 2000-04-03 2002-08-13 Schering Corporation Compositions of hepatitis C virus NS5B polymerase and methods for crystallizing same
US6448281B1 (en) * 2000-07-06 2002-09-10 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
EP1256628A3 (en) * 2001-05-10 2003-03-19 Agouron Pharmaceuticals, Inc. Hepatitis c virus (hcv) ns5b rna polymerase and mutants thereof
WO2003007945A1 (en) * 2001-07-20 2003-01-30 Boehringer Ingelheim (Canada) Ltd. Viral polymerase inhibitors
CA2459890A1 (en) * 2001-09-06 2003-03-20 Biogen Idec Ma Inc. Crystal structure of baff, and use thereof in drug design
US7223785B2 (en) * 2003-01-22 2007-05-29 Boehringer Ingelheim International Gmbh Viral polymerase inhibitors

Also Published As

Publication number Publication date
IL171800A (en) 2013-06-27
CN100457776C (zh) 2009-02-04
CN1820022A (zh) 2006-08-16
MXPA05012101A (es) 2006-02-08
EP1625154A1 (en) 2006-02-15
WO2004099241A1 (en) 2004-11-18
KR20060011861A (ko) 2006-02-03
ES2456702T3 (es) 2014-04-23
US20050003348A1 (en) 2005-01-06
AU2004235848A1 (en) 2004-11-18
CA2522574A1 (en) 2004-11-18
KR101164070B1 (ko) 2012-07-12
CA2522574C (en) 2015-07-07
EP1625154B1 (en) 2014-01-08
US7386398B2 (en) 2008-06-10
AU2004235848B2 (en) 2011-08-04
JP4584909B2 (ja) 2010-11-24
JP2007534292A (ja) 2007-11-29

Similar Documents

Publication Publication Date Title
DK1625154T3 (da) Hepatitis c virus ns5b-polymeraseinhibitor-bindende lomme
NO20053892D0 (no) Virale polymeraseinhibitorer
IS8476A (is) Lifrarbólgu C-veirutálmar
IS8475A (is) Lifrarbólgu C-veirutálmar
ATE506104T1 (de) Hepatitis-c-virus-hemmer
DK1718608T3 (da) Virale polymeraseinhibitorer
NO20040322L (no) Virus-polymerase-inhibitorer
AP2406A (en) Macrocydic inhibitors of hepatitis C virus.
ZA200607134B (en) Inhibitors of hepatitis C virus NS3 protease
ZA200609578B (en) Viral polymerase inhibitors
DK1912997T3 (da) Makrocycliske inhibitorer af hepatitis C virus
DK1919898T3 (da) Makrocykliske inhibitorer af hepatitis-C-virus
DK1912996T3 (da) Makrocykliske inhibitorer af hepatitis C-virus
DK1912981T3 (da) Makrocykliske inhibitorer af Hepatitis C-virus
DK1912995T3 (da) Makrocykliske inhibitorer af hepatitis C virus
DK1919899T3 (da) Makrocykliske inhibitorer af hepatitis C virus
DK1913014T3 (da) Makrocykliske inhibitorer af hepatitis-c-virus
HK1098512A1 (en) Determination of hepatitis c virus genotype
NO20055023D0 (no) Hurtigskytende vapen
DE602005009803D1 (de) N von schutztinte
DE602004000485D1 (de) Nachverbrennungsvorrichtung
DE602004004180D1 (de) Knüppelhalter
SE0400018D0 (sv) HCV polymerase inhibitors
ITMI20031633A1 (it) Inibitori di hcv ns5b polimerasi.
FR2857849B1 (fr) Pelle-ecope